HomeCompareCRGX vs PFE

CRGX vs PFE: Dividend Comparison 2026

CRGX yields 44.74% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRGX wins by $249.7K in total portfolio value
10 years
CRGX
CRGX
● Live price
44.74%
Share price
$4.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$299.2K
Annual income
$55,447.86
Full CRGX calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CRGX vs PFE

📍 CRGX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRGXPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRGX + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRGX pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRGX
Annual income on $10K today (after 15% tax)
$3,803.13/yr
After 10yr DRIP, annual income (after tax)
$47,130.68/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CRGX beats the other by $24,810.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRGX + PFE for your $10,000?

CRGX: 50%PFE: 50%
100% PFE50/50100% CRGX
Portfolio after 10yr
$174.4K
Annual income
$40,853.29/yr
Blended yield
23.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CRGX
Analyst Ratings
6
Hold
1
Sell
Consensus: Hold
Price Target
$23.00
+414.5% upside vs current
Range: $7.00 — $34.00
Altman Z
3.1
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRGX buys
0
PFE buys
0
No recent congressional trades found for CRGX or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRGXPFE
Forward yield44.74%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$299.2K$49.6K
Annual income after 10y$55,447.86$26,258.71
Total dividends collected$232.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$23.00$27.50

Year-by-year: CRGX vs PFE ($10,000, DRIP)

YearCRGX PortfolioCRGX Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$15,174$4,474.27$9,153$693.39+$6.0KCRGX
2$22,582$6,345.22$8,593$849.25+$14.0KCRGX
3$32,987$8,824.93$8,336$1,066.78+$24.7KCRGX
4$47,345$12,048.10$8,437$1,384.80+$38.9KCRGX
5$66,819$16,160.60$9,013$1,875.40+$57.8KCRGX
6$92,813$21,315.98$10,306$2,680.72+$82.5KCRGX
7$126,981$27,671.12$12,820$4,101.38+$114.2KCRGX
8$171,251$35,381.27$17,673$6,826.70+$153.6KCRGX
9$227,833$44,594.79$27,543$12,591.86+$200.3KCRGX
10$299,229$55,447.86$49,560$26,258.71+$249.7KCRGX

CRGX vs PFE: Complete Analysis 2026

CRGXStock

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Full CRGX Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CRGX vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRGX vs SCHDCRGX vs JEPICRGX vs OCRGX vs KOCRGX vs MAINCRGX vs JNJCRGX vs MRKCRGX vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.